NETRIS Pharma has dosed the first patient in its GYNet Phase 1b/II clinical study of NP137

LYON, FRANCE, December 31, 2020 /⁨EINPresswire.com⁩/ — NETRIS Pharma, a clinical-stage biopharmaceutical company developing therapeutics based on …
NETRIS Pharma First Patient Dosed in Phase Ib/II GYNet Study of NP137 in combination with chemotherapy and/or KEYTRUDA®